Like glucokinase, certain key mutations in this enzyme are of clinical relevance, as those that reduce sensitivity to the allosteric inhibitor GTP are associated with hyperinsulinism/hyperammonemia syndrome [80]–[83]. The gene discussed is GCK; the disease is hyperinsulinism.